This intellectual property portfolio of Stanford technologies encompasses a range of innovative therapies targeting various aspects of metabolic disorders and related conditions. The portfolio includes novel approaches for the treatment of cardiac dysfunction, diabetes, stroke, obesity, and fatty liver disease. These technologies span from small molecule inhibitors and targeted drug delivery systems to cell-based therapies and gene editing tools, offering multiple avenues for addressing the underlying mechanisms of these disorders. The portfolio also features advanced diagnostic and monitoring methods, enabling personalized treatment strategies for improved patient care.
This collection features inventions from pioneering researchers such as Michael Snyder, Sean Wu, Lars Steinmetz, Irving Weissman, Avnesh Thakor, Gerlinde Wernig, Jonathan Long, and Katrin Svensson.